A detailed history of Eqis Capital Management, Inc. transactions in Incyte Corp stock. As of the latest transaction made, Eqis Capital Management, Inc. holds 16,092 shares of INCY stock, worth $1.19 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares
16,092
Holding current value
$1.19 Million
% of portfolio
0.09%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$57.33 - $68.61 $922,554 - $1.1 Million
16,092 New
16,092 $1.06 Million
Q2 2022

Aug 08, 2022

SELL
$66.18 - $83.18 $23,163 - $29,113
-350 Reduced 5.98%
5,503 $0
Q1 2022

May 16, 2022

SELL
$66.02 - $79.71 $97,577 - $117,811
-1,478 Reduced 20.16%
5,853 $465,000
Q4 2021

Feb 14, 2022

SELL
$63.34 - $74.11 $138,397 - $161,930
-2,185 Reduced 22.96%
7,331 $538,000
Q3 2021

Nov 12, 2021

BUY
$68.67 - $84.02 $653,463 - $799,534
9,516 New
9,516 $655,000
Q3 2019

Nov 05, 2019

SELL
$72.82 - $86.52 $303,513 - $360,615
-4,168 Closed
0 $0
Q2 2019

Jul 18, 2019

SELL
$73.52 - $88.7 $15,071 - $18,183
-205 Reduced 4.69%
4,168 $354,000
Q1 2019

Apr 18, 2019

BUY
$63.56 - $88.17 $277,947 - $385,567
4,373 New
4,373 $376,000
Q4 2018

Jan 25, 2019

SELL
$58.5 - $69.94 $386,860 - $462,513
-6,613 Closed
0 $0
Q3 2018

Oct 17, 2018

BUY
$61.75 - $74.23 $408,352 - $490,882
6,613 New
6,613 $488,000
Q2 2018

Jul 27, 2018

SELL
$60.85 - $83.98 $1.2 Million - $1.66 Million
-19,757 Closed
0 $0
Q1 2018

Apr 06, 2018

BUY
$83.06 - $100.98 $25,167 - $30,596
303 Added 1.56%
19,757 $1.65 Million
Q4 2017

Jan 25, 2018

SELL
$93.56 - $116.6 $186,465 - $232,383
-1,993 Reduced 9.29%
19,454 $1.84 Million
Q3 2017

Oct 03, 2017

BUY
$109.15 - $138.27 $2.34 Million - $2.97 Million
21,447
21,447 $2.5 Million

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $16.4B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Eqis Capital Management, Inc. Portfolio

Follow Eqis Capital Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eqis Capital Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Eqis Capital Management, Inc. with notifications on news.